Gareth P. Gregory

3.2k total citations
74 papers, 956 citations indexed

About

Gareth P. Gregory is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Gareth P. Gregory has authored 74 papers receiving a total of 956 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pathology and Forensic Medicine, 46 papers in Oncology and 29 papers in Genetics. Recurrent topics in Gareth P. Gregory's work include Lymphoma Diagnosis and Treatment (47 papers), Chronic Lymphocytic Leukemia Research (24 papers) and CAR-T cell therapy research (21 papers). Gareth P. Gregory is often cited by papers focused on Lymphoma Diagnosis and Treatment (47 papers), Chronic Lymphocytic Leukemia Research (24 papers) and CAR-T cell therapy research (21 papers). Gareth P. Gregory collaborates with scholars based in Australia, United States and Canada. Gareth P. Gregory's co-authors include Ricky W. Johnstone, Jake Shortt, Lev M. Kats, Stephen Opat, Stephin J. Vervoort, Eva Vidacs, Chan Y. Cheah, Matthew Ku, Lihua E. Budde and Mazyar Shadman and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Gareth P. Gregory

65 papers receiving 946 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gareth P. Gregory Australia	16	495	421	290	221	184	74	956
Kamel Laribi France	17	606 1.2×	329 0.8×	336 1.2×	321 1.5×	604 3.3×	62	1.2k
Simone Ferrero Italy	18	462 0.9×	583 1.4×	347 1.2×	270 1.2×	390 2.1×	82	1.3k
Craig A. Portell United States	16	322 0.7×	409 1.0×	154 0.5×	281 1.3×	117 0.6×	65	765
Unn‐Merete Fagerli Norway	13	278 0.6×	201 0.5×	286 1.0×	138 0.6×	261 1.4×	33	744
Lorenzo Falchi United States	20	569 1.1×	707 1.7×	244 0.8×	520 2.4×	257 1.4×	113	1.3k
Geoffrey Chong Australia	15	393 0.8×	307 0.7×	151 0.5×	179 0.8×	95 0.5×	59	769
Adam M. Petrich United States	17	388 0.8×	554 1.3×	180 0.6×	221 1.0×	61 0.3×	57	902
Ferdinando Frigeri Italy	19	339 0.7×	437 1.0×	211 0.7×	483 2.2×	422 2.3×	60	1.2k
Ilse Christiansen Denmark	14	227 0.5×	438 1.0×	192 0.7×	229 1.0×	152 0.8×	31	789
Reem Karmali United States	17	559 1.1×	647 1.5×	137 0.5×	192 0.9×	62 0.3×	116	1.0k

Countries citing papers authored by Gareth P. Gregory

Since Specialization

Citations

This map shows the geographic impact of Gareth P. Gregory's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gareth P. Gregory with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gareth P. Gregory more than expected).

Fields of papers citing papers by Gareth P. Gregory

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gareth P. Gregory. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gareth P. Gregory. The network helps show where Gareth P. Gregory may publish in the future.

Co-authorship network of co-authors of Gareth P. Gregory

This figure shows the co-authorship network connecting the top 25 collaborators of Gareth P. Gregory. A scholar is included among the top collaborators of Gareth P. Gregory based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gareth P. Gregory. Gareth P. Gregory is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grigoriadis, George, Shaun Fleming, Pasquale L. Fedele, et al.. (2025). Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach. Internal Medicine Journal. 55(5). 749–759.

Shortt, Jake, et al.. (2025). Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury. Journal of Antimicrobial Chemotherapy. 80(12). 3462–3464.

Timmerman, John M., David Lavie, Gareth P. Gregory, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7055–7055. 2 indexed citations

Timmerman, John M., David Lavie, Nathalie A. Johnson, et al.. (2024). A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.. Journal of Clinical Oncology. 42(16_suppl). 7056–7056. 1 indexed citations

Falchi, Lorenzo, Patricia Walker, Gareth P. Gregory, et al.. (2024). A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.. Journal of Clinical Oncology. 42(16_suppl). TPS7095–TPS7095. 1 indexed citations

Churilov, Leonid, Andrew Grigg, Joel Wight, et al.. (2024). Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study. British Journal of Haematology. 205(1). 146–157. 3 indexed citations

Gregory, Gareth P., Jeremy S. Abramson, Huiqiang Huang, et al.. (2024). Primary Results of Patient-Reported Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) Versus Rituximab Plus GemOx (R-GemOx) from the Phase III Starglo Study. Blood. 144(Supplement 1). 5132–5132.

Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253. 10 indexed citations

Johnson, Nathalie A., David Lavie, Peter Borchmann, et al.. (2023). Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study. Blood. 142(Supplement 1). 1693–1693. 3 indexed citations

10.

Kwan, Edward, et al.. (2022). Cytoreductive Surgery for Primary Central Nervous System Lymphoma: Is it time to consider extent of resection?. Journal of Clinical Neuroscience. 106. 110–116. 2 indexed citations

11.

Bjelosevic, Stefan, Andrea Newbold, Jennifer R. Devlin, et al.. (2021). Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD–Driven Acute Myeloid Leukemia. Cancer Discovery. 11(6). 1582–1599. 50 indexed citations

12.

Budde, Elizabeth, Ajay K. Gopal, Won Seog Kim, et al.. (2021). A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 138(Supplement 1). 132–132. 22 indexed citations

13.

Gregory, Gareth P., Anna Pierce, Julian Druce, et al.. (2021). Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient. Infection Control and Hospital Epidemiology. 43(6). 820–822. 4 indexed citations

14.

Gregory, Gareth P., Shaji Kumar, Ding Wang, et al.. (2021). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances. 6(4). 1232–1242. 24 indexed citations

15.

Gregory, Gareth P., Constantine S. Tam, Hang Quach, et al.. (2020). Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy. Leukemia & lymphoma. 62(1). 112–117. 8 indexed citations

16.

Kelly, Madison J., Joan So, Gareth P. Gregory, et al.. (2019). Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis. Nature Communications. 10(1). 1347–1347. 44 indexed citations

17.

Kats, Lev M., Stephin J. Vervoort, Rachel M. Cole, et al.. (2017). A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML. Leukemia. 31(6). 1466–1470. 23 indexed citations

18.

Hogg, Simon J., Andrea Newbold, Stephin J. Vervoort, et al.. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. 15(9). 2030–2041. 50 indexed citations

19.

Baker, Adele, Gareth P. Gregory, Inge Verbrugge, et al.. (2015). The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research. 76(5). 1158–1169. 83 indexed citations

20.

Gregory, Gareth P., Kah Lok Chan, Constantine S. Tam, et al.. (2013). Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro-Oncology. 15(8). 1068–1073. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact